BNTC Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	19 742.00
Średni wolumen	82 838.00
Kapitalizacja rynkowa	17.89M
EPS	$0 ( 2024-02-12 )
Następna data zysków	( $-0.780 ) 2024-05-13
Last Dividend	$0.0450 ( 2018-06-01 )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.0330 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Banks Jerel A.	Buy	466 554	Options (right to buy)
2024-03-06	Boston Megan	Buy	200 004	Options (right to buy)
2023-12-06	Smith Edward F	Buy	35 000	Options (right to buy)
2023-12-06	Francis Peter	Buy	35 000	Options (right to buy)
2023-12-06	Buchi J Kevin	Buy	35 000	Options (right to buy)

INSIDER POWER
100.00
Last 38 transactions
Buy: 2 361 696 \| Sell: 57 465

Wolumen Korelacja

Długi: -0.17 (neutral)

Krótki: -0.39 (neutral)

Signal:(48.426) Neutral

Benitec Biopharma Inc Korelacja

10 Najbardziej pozytywne korelacje
RNLX	0.862
TTSH	0.842
BAFN	0.831
OVLY	0.829
VIOT	0.826
GGAL	0.826
ASLE	0.824
CASH	0.823
BOOM	0.82
TELA	0.818

10 Najbardziej negatywne korelacje
MBCN	-0.811

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Benitec Biopharma Inc Korelacja - Waluta/Towar

0.15
( neutral )

0.10
( neutral )

0.00
( neutral )

0.36
( neutral )

-0.14
( neutral )

-0.43
( neutral )

Benitec Biopharma Inc Finanse

Annual	2023
Przychody:	$75 000.00
Zysk brutto:	$-306 000 (-408.00 %)
EPS:	$-14.12

FY	2023
Przychody:	$75 000.00
Zysk brutto:	$-306 000 (-408.00 %)
EPS:	$-14.12

FY	2022
Przychody:	$73 000.00
Zysk brutto:	$64 000.00 (87.67 %)
EPS:	$-38.62

FY	2021
Przychody:	$59 000.00
Zysk brutto:	$-64 000.00 (-108.47 %)
EPS:	$-3.23

Financial Reports:

No articles found.

Benitec Biopharma Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Benitec Biopharma Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0450	2018-06-01
Last Dividend	$0.0450	2018-06-01
Next Dividend	$0	N/A
Payout Date	2018-06-08
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0450	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2018	$0.0450	0.01%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-358.57	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-1.024	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-2.05	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.62	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.55	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.55	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0198	-1.500	9.67	-10.00	[0 - 0.6]
interestCoverageTTM	-1 446.13	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-7.01	2.00	-2.34	-4.67	[0 - 30]
freeCashFlowPerShareTTM	-7.01	2.00	-3.51	-7.01	[0 - 20]
debtEquityRatioTTM	0.0273	-1.500	9.89	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.820	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-355.61	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-42.71	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00286	0.800	-3.31	-2.65	[0.5 - 2]
Total Score				-1.934

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.813	1.000	-0.183	0	[1 - 100]
returnOnEquityTTM	-2.05	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-7.01	2.00	-2.34	-7.01	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-7.01	2.00	-2.34	-4.67	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00690	1.500	-3.29	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-296.16	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-3.45

Benitec Biopharma Inc

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.